These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 28703335)
21. Immunohistochemical distinction of primary sweat gland carcinoma and metastatic breast carcinoma: can it always be accomplished reliably? Mentrikoski MJ; Wick MR Am J Clin Pathol; 2015 Mar; 143(3):430-6. PubMed ID: 25696802 [TBL] [Abstract][Full Text] [Related]
22. TRPS1 is a promising marker for all subtypes of breast cancer. Lui JW; Tsang JY; Li J; Ko CW; Tam F; Loong TC; Tse GM Histopathology; 2024 Apr; 84(5):822-836. PubMed ID: 38173281 [TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical evaluation of GATA-3 expression in ER-negative breast carcinomas. Liu H; Shi J; Prichard JW; Gong Y; Lin F Am J Clin Pathol; 2014 May; 141(5):648-55. PubMed ID: 24713735 [TBL] [Abstract][Full Text] [Related]
24. Simultaneous carcinomas of the breast and ovary: utility of Pax-8, WT-1, and GATA3 for distinguishing independent primary tumors from metastases. Espinosa I; Gallardo A; D'Angelo E; Mozos A; Lerma E; Prat J Int J Gynecol Pathol; 2015 May; 34(3):257-65. PubMed ID: 25844549 [TBL] [Abstract][Full Text] [Related]
25. GATA3 expression in morphologic subtypes of breast carcinoma: a comparison with gross cystic disease fluid protein 15 and mammaglobin. Wendroth SM; Mentrikoski MJ; Wick MR Ann Diagn Pathol; 2015 Feb; 19(1):6-9. PubMed ID: 25544392 [TBL] [Abstract][Full Text] [Related]
26. GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer. Ni YB; Tsang JYS; Shao MM; Chan SK; Cheung SY; Tong J; To KF; Tse GM Breast Cancer Res Treat; 2018 May; 169(1):25-32. PubMed ID: 29340880 [TBL] [Abstract][Full Text] [Related]
27. Utility of GATA-3 in the work-Up of breast adenocarcinoma and its differential diagnosis in serous effusions:: A Cell-Block Microarray Study. El Hag MI; Ha J; Farag R; El Hag AM; Michael CW Diagn Cytopathol; 2016 Sep; 44(9):731-6. PubMed ID: 27338760 [TBL] [Abstract][Full Text] [Related]
28. GATA3 expression in advanced breast cancer: prognostic value and organ-specific relapse. McCleskey BC; Penedo TL; Zhang K; Hameed O; Siegal GP; Wei S Am J Clin Pathol; 2015 Nov; 144(5):756-63. PubMed ID: 26486740 [TBL] [Abstract][Full Text] [Related]
29. GATA-binding protein 3 enhances the utility of gross cystic disease fluid protein-15 and mammaglobin A in triple-negative breast cancer by immunohistochemistry. Huo L; Gong Y; Guo M; Gilcrease MZ; Wu Y; Zhang H; Zhang J; Resetkova E; Hunt KK; Deavers MT Histopathology; 2015 Aug; 67(2):245-54. PubMed ID: 25564996 [TBL] [Abstract][Full Text] [Related]
30. TRPS1 expression in cytokeratin 5 expressing triple negative breast cancers, its value as a marker of breast origin. Almási S; Kuthi L; Sejben A; Vörös A; Nagy Á; Zombori T; Cserni G Virchows Arch; 2023 May; 482(5):861-868. PubMed ID: 37012444 [TBL] [Abstract][Full Text] [Related]
31. A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancer. Tozbikian GH; Zynger DL Hum Pathol; 2019 Mar; 85():221-227. PubMed ID: 30468800 [TBL] [Abstract][Full Text] [Related]
32. GATA3 is a sensitive marker for primary genital extramammary paget disease: an immunohistochemical study of 72 cases with comparison to gross cystic disease fluid protein 15. Zhao M; Zhou L; Sun L; Song Y; Guo Y; Zhang X; Zhao F; Wang P; Yue J; Niu D; Li Z; Huang X; Kang Q; Jia L; Lai J; Cao D Diagn Pathol; 2017 Jul; 12(1):51. PubMed ID: 28693610 [TBL] [Abstract][Full Text] [Related]
33. Diagnostic utility and sensitivities of GATA3 antibodies in triple-negative breast cancer. Krings G; Nystrom M; Mehdi I; Vohra P; Chen YY Hum Pathol; 2014 Nov; 45(11):2225-32. PubMed ID: 25150746 [TBL] [Abstract][Full Text] [Related]
34. Significantly increased PELP1 protein expression in primary and metastatic triple-negative breast carcinoma: comparison with GATA3 expression and PELP1's potential role in triple-negative breast carcinoma. Dang DN; Raj G; Sarode V; Molberg KH; Vadlamudi RK; Peng Y Hum Pathol; 2015 Dec; 46(12):1829-35. PubMed ID: 26428280 [TBL] [Abstract][Full Text] [Related]
35. Diagnostic utility and sensitivities of matrix Gla protein (MGP), TRPS1 and GATA3 in breast cancer: focusing on metastatic breast cancer, invasive breast carcinoma with special features, and salivary gland-type tumours. Wu Y; Chen F; Pan L; Chao X; Li M; Luo R; Chen K; Zheng C; Du T; He J; Sun P Pathology; 2024 Jun; 56(4):516-527. PubMed ID: 38570266 [TBL] [Abstract][Full Text] [Related]
36. Combined SOX10 GATA3 is most sensitive in detecting primary and metastatic breast cancers: a comparative study of breast markers in multiple tumors. Aphivatanasiri C; Li J; Chan R; Jamidi SK; Tsang JY; Poon IK; Shao Y; Tong J; To KF; Chan SK; Tam F; Cheung SY; Shea KH; Tse GM Breast Cancer Res Treat; 2020 Nov; 184(1):11-21. PubMed ID: 32737715 [TBL] [Abstract][Full Text] [Related]
37. The utility of villin and mammaglobin in the differential diagnosis between intrahepatic cholangiocarcinoma and breast cancer. Yang Z Appl Immunohistochem Mol Morphol; 2015 Jan; 23(1):19-25. PubMed ID: 25153498 [TBL] [Abstract][Full Text] [Related]
38. SOX10, GATA3, GCDFP15, Androgen Receptor, and Mammaglobin for the Differential Diagnosis Between Triple-negative Breast Cancer and TTF1-negative Lung Adenocarcinoma. Laurent E; Begueret H; Bonhomme B; Veillon R; Thumerel M; Velasco V; Brouste V; Hoppe S; Fournier M; Grellety T; MacGrogan G Am J Surg Pathol; 2019 Mar; 43(3):293-302. PubMed ID: 30628926 [TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas. Liu H; Shi J; Wilkerson ML; Lin F Am J Clin Pathol; 2012 Jul; 138(1):57-64. PubMed ID: 22706858 [TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical Markers for Distinguishing Metastatic Breast Carcinoma from Other Common Malignancies: Update and Revisit. Ding Q; Huo L; Peng Y; Yoon EC; Li Z; Sahin AA Semin Diagn Pathol; 2022 Sep; 39(5):313-321. PubMed ID: 35461734 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]